Low-dose CT Lung Cancer Screening in France for 50–74-Year-Old Smokers
Official title: Implementing Low-dose ct Lung Cancer Screening in France.
Run by Assistance Publique - Hôpitaux de Paris · NCT07513818 · Data updated 2026-11-12
This study tests whether offering low-dose chest CT screening to adults aged 50–74 who smoke or recently quit is feasible and safe at a population level.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 74 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 2 sites (Lyon, France and 1 other locations) |
| Status | Recruiting |
| Started | May 11, 2026 |
| Main results expected | May 2031 |
| Study ends | November 2031 |
| Registry record updated | June 5, 2026 |
| Trial ID | NCT07513818 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 50–74 years old who currently smoke or quit within the last 15 years, have a substantial smoking history, and are affiliated with a social security scheme.
✕Probably not a fit
Individuals outside the age range, with recent chest CTs, or with conditions that preclude safe screening or follow-up may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial focuses on implementing LDCT screening for lung cancer across selected French centers and tests recruitment, invitation methods, and the use of artificial intelligence as an alternative to double human reading. Participants will receive baseline LDCT, a follow-up at one year, and a third LDCT two years later, with smoking-cessation support offered to current smokers. Management of detected nodules will follow 2025 European guidelines. The study is not powered to prove mortality reduction but aims to demonstrate safe, equitable, and scalable population-level screening. Primary objective is to estimate the detection rate of lung cancer in the screened population, while also examining practical and operational aspects of rollout.
Why it matters
Potential benefit: If successful, the approach could enable safer, larger-scale lung cancer screening programs that identify cancers earlier and more equitably.
How similar studies have gone: Previous LDCT trials showed mortality reduction; this study builds on that by testing population-wide implementation and AI-assisted reading, which is novel in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 50-74 years * Active or former smoker having quit less than 15 years ago * Smoking history of at least 20 pack-years, or 15 cigarettes/day for 25 years or 10 cigarettes/day for 30 years * Affiliation with a social security scheme * Written informed consent prior to study participation Temporary exclusion Criteria * Chest CT scan performed within the previous 12 months * Signs of respiratory infection (fever, productive cough) Exclusion Criteria: * Severe co-morbidities contraindicating exploration and/or management (including stereotactic surgery or radiotherapy) of lung cancers * Poor general status (PS2 and above) * Rest dyspnea (mMRC4) * Cancer under active surveillance by thoracic computed tomography (CT pr PET-CT) * Personal history of lung cancer * Symptoms raising suspicion of lung cancer (hemoptysis, unexplained weight loss, recent onset or modification of respiratory symptoms,…)
Where it's running
-
Hôpital Cochin
Paris, Île-de-France Region, France Recruiting -
HCL - Hôpital Lyon Sud
Lyon, France, France Not yet recruiting
Study contacts
- Principal investigator: Marie-Pierre REVEL, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Marie-Pierre REVEL, PhD
- Email: marie-pierre.revel@aphp.fr
- Phone: 01 58 41 24 71
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.